Rabbit Work in Wet AMD Research in the MICRON Literature

About the MICRON Research Literature

These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.

All publication counts and figures reflect the complete indexed research collection.

Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.

Understanding Wet AMD

Neovascular AMD is a human disease of the macula, involving new vessel growth that most commonly arises from the choroid, either remaining beneath the retinal pigment epithelium or entering the subretinal space, with a third form originating in the retinal circulation.

Where the vessels leak, that leakage is directly imageable, which is why angiography recurs as a readout in this literature.

Wet AMD in Experimental Research

The species here have no macula, so this work models components of neovascular AMD, most directly the neovascular process, without reproducing the macular anatomy of the human disease.

In much of this literature choroidal neovascularization is induced by laser and read out in a non-macular retina.

Rabbit in Wet AMD Research

The rabbit eye is much larger than a rodent's, which makes it a practical model for ocular pharmacokinetics and for procedures that need working space.

It is not a small human eye: vitreous volume is roughly a third of the human figure, and vitreous composition and retinal vascular anatomy differ substantially.

Published MICRON Research: Wet AMD in Rabbits

This page lists 10 papers from the MICRON literature, published 2013 to 2025, that study neovascular (wet) age-related macular degeneration in rabbits.

Of these publications:

  • 1 study used rabbits as the primary wet age-related macular degeneration disease model.
  • 9 studies used healthy animals to assess pharmacokinetics, drug delivery, or tolerability.

Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published wet age-related macular degeneration research.

Which imaging and experimental techniques are used in these studies?

Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.

Capabilities and Limitations of Imaging Techniques

A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.

Intravitreal Injection / Delivery

Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.

Fundus Fluorescein Angiography

Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.

This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.

Laser Photocoagulation Models

A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease: it produces a lesion directly, bypassing the process that gives rise to comparable damage in patients.

Optical Coherence Tomography

Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.

As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).

Electroretinography

Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.

Topical Ophthalmic Drug Delivery

A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.

Which MICRON systems and add-ons appear?

Which MICRON systems and add-ons appear?
Instrument Papers
MICRON IV 7
Image-Guided OCT 4
MICRON III 4
Image-Guided Laser 3

Which strains and genetic lines are used?

Which strains and genetic lines are used?
Strain Papers Reported as
New Zealand White 6
New Zealand 3
Dutch Belted 1 Dutch belted

Which other species appear alongside?

Which other species appear alongside?
Species Papers
Mouse 9
Cynomolgus Macaque 3
Rat 3
Minipig 1

What other conditions are recorded on the same papers?

What other conditions are recorded on the same papers?
Disease Papers
Age-Related Macular Degeneration (General) 9
Choroidal Neovascularization 9
Retinal Neovascularization (General) 6
Diabetic Retinopathy 4
Corneal Neovascularization 1
Diabetes Mellitus, Type 1 1
Epiretinal Membrane 1
Retinal Detachment 1
Retinopathy of Prematurity 1

Which MICRON configurations appear in this work?

Configurations recorded in these papers, and the techniques recorded alongside them.

Which MICRON configurations appear in this work?
MICRON configuration Papers Most frequent techniques recorded alongside
MICRON IV 7 Intravitreal Injection / Delivery (7), Fundus Fluorescein Angiography (6), Laser Photocoagulation Models (4)
Image-Guided OCT 4 Fundus Fluorescein Angiography (4), Intravitreal Injection / Delivery (4), Optical Coherence Tomography (3)
MICRON III 4 Intravitreal Injection / Delivery (2), Fundus Fluorescein Angiography (2), Electroretinography (2)
Image-Guided Laser 3 Intravitreal Injection / Delivery (3), Laser Photocoagulation Models (2), Fundus Fluorescein Angiography (2)

The papers

The papers
Year Title Journal Role of focal species MICRON products Links
2025 Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage. Molecular Therapy Healthy PK, delivery or tolerability Image-Guided Laser, MICRON IV DOI · reSEARCH
2025 PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases. Nature Communications Healthy PK, delivery or tolerability Image-Guided Laser, Image-Guided OCT, MICRON IV DOI · reSEARCH
2024 An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species. Nature Communications Healthy PK, delivery or tolerability Image-Guided OCT, MICRON IV DOI · reSEARCH
2022 Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders. Ophthalmology Science Healthy PK, delivery or tolerability Image-Guided OCT, MICRON IV DOI · reSEARCH
2021 A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice. Pharmaceutics Healthy PK, delivery or tolerability Image-Guided Laser, MICRON IV DOI · reSEARCH
2021 A Novel Eye Drop Formulation for Potential Treatment of Neovascular Age-Related Macular Degeneration. Translational Vision Science & Technology Disease model Image-Guided OCT, MICRON III, MICRON IV DOI · reSEARCH
2020 Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. Nature Communications Healthy PK, delivery or tolerability MICRON III DOI · reSEARCH
2017 Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration. mAbs Healthy PK, delivery or tolerability MICRON III DOI · reSEARCH
2014 Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization. PLoS ONE Healthy PK, delivery or tolerability MICRON IV DOI · reSEARCH
2013 Sustained delivery of a HIF-1 antagonist for ocular neovascularization. Journal of Controlled Release Healthy PK, delivery or tolerability MICRON III DOI · reSEARCH

Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.

Last built 2026-11-10 from content tag hubs-content-2026-11-10 (ae06cfc); fact-sheet run sheets-20261110T111119Z. About these hubs Back to top